An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization.
This combination pairs Orforglipron (an oral non-peptide GLP-1 receptor agonist currently in Phase III clinical trials by Eli Lilly) with SLU-PP-332 (an ERRalpha/gamma agonist that mimics the molecular effects of endurance exercise). Orforglipron represents a major advance in metabolic medicine as the first oral non-peptide GLP-1 receptor agonist, potentially offering the weight loss benefits of injectable semaglutide (Ozempic/Wegovy) in a convenient daily pill. Phase II data showed significant weight loss and glycemic improvements comparable to injectable GLP-1 agonists. SLU-PP-332 was identified in 2023 research as a potent activator of estrogen-related receptors that drives mitochondrial biogenesis and fat oxidation, mimicking the metabolic adaptations of endurance exercise training. Together, these two compounds address weight loss from complementary angles: Orforglipron reduces appetite and caloric intake through central GLP-1 signaling, while SLU-PP-332 increases the metabolic rate and fat oxidation capacity of peripheral tissues.
* Benefits based on preclinical/animal research unless otherwise noted.
“An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization.”
Orforglipron is a small molecule that directly binds to and activates the GLP-1 receptor (GLP1R), a G-protein coupled receptor expressed in the pancreas, brain, gut, and other tissues. GLP-1 receptor activation in the pancreas enhances glucose-stimulated insulin secretion; in the brain (hypothalamus and brainstem), it reduces appetite and food intake through multiple neuropeptide signaling pathways; in the gut, it slows gastric emptying to reduce post-meal glucose spikes. As a non-peptide small molecule, Orforglipron has high oral bioavailability unlike peptide GLP-1 agonists (semaglutide, liraglutide) that require injection. SLU-PP-332 activates ERRalpha and ERRgamma nuclear receptors, transcription factors that regulate hundreds of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation — essentially programming cells to burn more fat and produce more mitochondria, mimicking the molecular adaptations of endurance exercise.
Protocol Notes: Orforglipron is currently in Phase III trials. Requires physician supervision. Titrate slowly to minimize GI side effects.
Store at room temperature, away from light and moisture.
When sourcing Orforglipron + SLU-PP-332 (Capsule) for research purposes, the following quality benchmarks should be verified before use.
Store at room temperature, away from light and moisture.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Moderate Evidence — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.
Peptides commonly used alongside Orforglipron + SLU-PP-332 (Capsule) for synergistic effects.
NNMT Inhibitor
A small molecule NNMT inhibitor that promotes fat loss and metabolic health by raising cellular NAD+ levels.
Learn More: 5-Amino-1MQ (Capsule)Metabolic Optimization Complex
A triple metabolic complex targeting mitochondrial uncoupling, ERR agonism, and cellular aging for comprehensive metabolic optimization.
Learn More: BAM-15 + SLU-PP-332 + C15 (Capsule)